GlaxoSmithKline plc GSKand partner Innoviva, Inc. INVAannounced the submission of a regulatory application in Japan seeking approval for their once-daily, single inhaler triple combination therapy, Trelegy Ellipta for the treatment of chronic obstructive pulmonary disease (“COPD”) in adults.
Glaxo/Innoviva File for Approval of Trelegy Ellipta in Japan
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться